User login
Locked Knee Caused by Lateral Meniscal Capsular Disruption: Verification by Magnetic Resonance Imaging and Arthroscopy
Missed Locked Posterior Shoulder Dislocation With a Reverse Hill-Sachs Lesion and Subscapularis Rupture
Symptomatic Carpal Coalition: Scaphotrapezial Joint
Advanced Parkinson Disease— It’s More Than Just a Tremor
Renal failure in multiple myeloma
This report details the case of a 65-year-old man who was diagnosed with multiple myeloma in 2006 and since 2009, has attempted to control the progression of his disease with the most powerful available treatment regimens, including bortezomib-based regimens, for both induction and consolidation therapy followed by autologous stem-cell transplants. Subsequently, because the patient was deemed treatment refractory, treatment with the newly approved carfilzomib was initiated. Coincidentally, the patient developed acute kidney injury, evidenced by tenfold rise in his creatinine levels, 2 weeks after the initiation of carfilzomib.
Click on the PDF icon at the top of this introduction to read the full article.
This report details the case of a 65-year-old man who was diagnosed with multiple myeloma in 2006 and since 2009, has attempted to control the progression of his disease with the most powerful available treatment regimens, including bortezomib-based regimens, for both induction and consolidation therapy followed by autologous stem-cell transplants. Subsequently, because the patient was deemed treatment refractory, treatment with the newly approved carfilzomib was initiated. Coincidentally, the patient developed acute kidney injury, evidenced by tenfold rise in his creatinine levels, 2 weeks after the initiation of carfilzomib.
Click on the PDF icon at the top of this introduction to read the full article.
This report details the case of a 65-year-old man who was diagnosed with multiple myeloma in 2006 and since 2009, has attempted to control the progression of his disease with the most powerful available treatment regimens, including bortezomib-based regimens, for both induction and consolidation therapy followed by autologous stem-cell transplants. Subsequently, because the patient was deemed treatment refractory, treatment with the newly approved carfilzomib was initiated. Coincidentally, the patient developed acute kidney injury, evidenced by tenfold rise in his creatinine levels, 2 weeks after the initiation of carfilzomib.
Click on the PDF icon at the top of this introduction to read the full article.
Diffuse large B-cell lymphoma of the lung in a 63-year-old man with left flank pain
Diffuse large B-cell lymphoma of the lung is a rare entity, and although the prognosis is favorable, its biological features, clinical presentation, prognostic markers, and treatment have not been well defined.1,2 It is the second most common primary pulmonary lymphoma after mucosa-associated lymphoid tissue. PPL itself is very rare; it represents 3%-4% of extranodal non-Hodgkin lymphoma, less than 1% of NHL, and 0.5%-1.0% of primary pulmonary malignancies.2,3 A review of the literature indicates a lack of data on pulmonary DLBCL. The objective of this case report is to highlight areas in which further research may be pursued to better understand this disease.
Click on the PDF icon at the top of this introduction to read the full article.
Diffuse large B-cell lymphoma of the lung is a rare entity, and although the prognosis is favorable, its biological features, clinical presentation, prognostic markers, and treatment have not been well defined.1,2 It is the second most common primary pulmonary lymphoma after mucosa-associated lymphoid tissue. PPL itself is very rare; it represents 3%-4% of extranodal non-Hodgkin lymphoma, less than 1% of NHL, and 0.5%-1.0% of primary pulmonary malignancies.2,3 A review of the literature indicates a lack of data on pulmonary DLBCL. The objective of this case report is to highlight areas in which further research may be pursued to better understand this disease.
Click on the PDF icon at the top of this introduction to read the full article.
Diffuse large B-cell lymphoma of the lung is a rare entity, and although the prognosis is favorable, its biological features, clinical presentation, prognostic markers, and treatment have not been well defined.1,2 It is the second most common primary pulmonary lymphoma after mucosa-associated lymphoid tissue. PPL itself is very rare; it represents 3%-4% of extranodal non-Hodgkin lymphoma, less than 1% of NHL, and 0.5%-1.0% of primary pulmonary malignancies.2,3 A review of the literature indicates a lack of data on pulmonary DLBCL. The objective of this case report is to highlight areas in which further research may be pursued to better understand this disease.
Click on the PDF icon at the top of this introduction to read the full article.
